CA2155554A1 - Role de la proteolyse atp-ubiquitine-dependante dans la presentation de l'antigene a restriction mhc-1; inhibiteurs de celui-ci - Google Patents

Role de la proteolyse atp-ubiquitine-dependante dans la presentation de l'antigene a restriction mhc-1; inhibiteurs de celui-ci

Info

Publication number
CA2155554A1
CA2155554A1 CA002155554A CA2155554A CA2155554A1 CA 2155554 A1 CA2155554 A1 CA 2155554A1 CA 002155554 A CA002155554 A CA 002155554A CA 2155554 A CA2155554 A CA 2155554A CA 2155554 A1 CA2155554 A1 CA 2155554A1
Authority
CA
Canada
Prior art keywords
ubiquitin
inhibitor
cells
cleavage
mhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002155554A
Other languages
English (en)
Inventor
Alfred L. Goldberg
Kenneth L. Rock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Dana Farber Cancer Institute Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2155554A1 publication Critical patent/CA2155554A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CA002155554A 1993-02-10 1994-01-27 Role de la proteolyse atp-ubiquitine-dependante dans la presentation de l'antigene a restriction mhc-1; inhibiteurs de celui-ci Abandoned CA2155554A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1606693A 1993-02-10 1993-02-10
US08/016,066 1993-02-10

Publications (1)

Publication Number Publication Date
CA2155554A1 true CA2155554A1 (fr) 1994-08-18

Family

ID=21775196

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002155554A Abandoned CA2155554A1 (fr) 1993-02-10 1994-01-27 Role de la proteolyse atp-ubiquitine-dependante dans la presentation de l'antigene a restriction mhc-1; inhibiteurs de celui-ci

Country Status (5)

Country Link
EP (1) EP0684829A4 (fr)
JP (1) JPH08507754A (fr)
AU (1) AU676721B2 (fr)
CA (1) CA2155554A1 (fr)
WO (1) WO1994017816A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6287569B1 (en) 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
CA2219867A1 (fr) * 1997-10-31 1999-04-30 Jiangping Wu Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique
US5968747A (en) * 1997-12-12 1999-10-19 Incyte Pharmaceuticals, Inc. Ubiquitin-like conjugating protein
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
KR20010080267A (ko) 1998-10-20 2001-08-22 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아솜 억제제 약물 작용을 모니터링하는 방법
JP2002105080A (ja) * 2000-09-29 2002-04-10 Microbial Chem Res Found 生理活性物質パネポフェナンスリンとその製造法
US20050049294A1 (en) 2003-06-20 2005-03-03 Michael Palladino Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CN102725300B (zh) 2009-12-22 2015-03-11 赛福伦公司 蛋白酶体抑制剂及其制备、纯化、和应用的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390629A (en) * 1981-03-30 1983-06-28 President And Fellows Of Harvard College Polypeptide degrading enzymes
US5340736A (en) * 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting

Also Published As

Publication number Publication date
EP0684829A4 (fr) 1997-05-21
AU6169194A (en) 1994-08-29
JPH08507754A (ja) 1996-08-20
EP0684829A1 (fr) 1995-12-06
AU676721B2 (en) 1997-03-20
WO1994017816A1 (fr) 1994-08-18

Similar Documents

Publication Publication Date Title
Tschopp et al. Perforin-mediated target cell lysis by cytolytic T lymphocytes
Mueller et al. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis.
US5759994A (en) Recombinant thrombin receptor and related pharmaceuticals
US6325989B1 (en) Form of dipeptidylpeptidase IV (CD26) found in human serum
US20070128198A1 (en) Compositions comprising antibodies to human fgl2
CA2270291A1 (fr) Kallikreine specifique de la prostate
CA2155554A1 (fr) Role de la proteolyse atp-ubiquitine-dependante dans la presentation de l'antigene a restriction mhc-1; inhibiteurs de celui-ci
WO1993024634A1 (fr) Dipeptidyle peptidase-i, son clonage et agents therapeutiques contenant des inhibiteurs de cette substance
RU2194713C2 (ru) Модифицированный c3 белок человека, фрагмент днк, конъюгат, фармацевтическая композиция, способ уменьшения количества белка
CA2136981A1 (fr) Adn codant pour l'enzyme de conversion de l'interleukine 1.beta. precurseur
US6451759B1 (en) Noncleavable Fas ligand
AU711586B2 (en) Mocarhagin, a cobra venom protease, and therapeutic uses thereof
JP2003313199A (ja) コラーゲン誘発血小板凝集抑制剤
WO1998002579A1 (fr) Regulation de l'apoptose et modele in vitro destine a des recherches en la matiere
Raju et al. Myristoyl-CoA: ProteinN-Myristoyltransferase from Bovine Cardiac Muscle: Molecular Cloning, Kinetic Analysis, andin VitroProteolytic Cleavage bym-Calpain
WO1998002579A9 (fr) Regulation de l'apoptose et modele in vitro destine a des recherches en la matiere
Fruth et al. The T cell‐specific serine proteinase TSP‐1 is associated with cytoplasmic granules of cytolytic T lymphocytes
WO2000063227A1 (fr) Variante d'epissage de metalloproteinase-5 (mt-mmp5-l) de matrice humaine de type membrane
Shibata et al. Disruption of structural and functional integrity of α2‐macroglobulin by cathepsin E
AU732547B2 (en) Novel cyclin-selective ubiquitin carrier polypeptides
US6558900B2 (en) Regulation of apoptosis and in vitro model for studies thereof
US6180379B1 (en) Cyclin-selective ubiquitin carrier polypeptides
Jackson et al. Assembly and intracellular transport of MHC class I and class II molecules
AU6914600A (en) Peptide and peptide analogues for the treatment and prevention of diabetes
AU727222B2 (en) Regulation of apoptosis and in vitro model for studies thereof

Legal Events

Date Code Title Description
FZDE Dead